GSK's $1 billion acquisition of IDRx includes IDRX-42, a precision therapy for GIST. Phase 1/1b trial shows 53% ORR in early treatment stages.

GSK has upgraded its longstanding alliance with ... Merck eyes deal with Afrigen Biologics In other mRNA vaccine news today, Germany’s Merck KGaA revealed that it has signed a non-binding ...

Shares in pharmaceutical company GlaxoSmithKline (GSK ... another major US pharmaceutical company, and Germany-based ...

GSK (GSK) and IDRx announced that they have entered into an agreement under which GSK will acquire IDRx. Under the agreement, GSK will pay $1B ...

The €150 million collaboration between UK pharma GSK and Germany’s CureVac builds on their existing relationship and will jointly develop next generation mRNA vaccines. It will attempt to ...

GSK has announced that the European Medicines Agency (EMA) has accepted its regulatory application for a prefilled syringe presentation of Shingrix ...

London: GSK plc has announced that they have entered into an agreement under which GSK will acquire IDRx, a Boston-based, ...

GSK to acquire Boston-based, clinical-stage biopharma company, IDRx for up to $1.15 billion: London, UK Monday, January 13, 2025, 13:35 Hrs [IST] GSK plc and IDRx, Inc. (IDRx) ann ...

GSK’s vaccine portfolio. GSK’s portfolio of more than 20 marketed vaccines, one of the industry’s broadest, protects people against diseases such as meningitis, shingles, polio, measles ...

GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx) today announced that they have entered into an agreement under which GSK will acquire IDRx, a Boston-based, clinical-stage biopharmaceutical company ...